Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 in Moderate to Severe Platysma Prominence
NCT07122193Phase 3Active, not recruiting
- Sponsor
- Merz
- Start
- Aug 2025
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of incobotulinumtoxinA in platysma prominence, sponsored by Merz. Started Aug 2025; status: active, not recruiting.
02
Drugs
incobotulinumtoxinA
03
Conditions
platysma prominence
Beyond the preview
Go deeper on NCT07122193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07122193.